From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
about
Structural and mutational analysis of the interaction between the Middle-East respiratory syndrome coronavirus (MERS-CoV) papain-like protease and human ubiquitinPotent and selective inhibition of pathogenic viruses by engineered ubiquitin variants.Crystallization and preliminary crystallographic study of Feline infectious peritonitis virus main protease in complex with an inhibitorStructures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity.Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.A G-quadruplex-binding macrodomain within the "SARS-unique domain" is essential for the activity of the SARS-coronavirus replication-transcription complex.Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design.RNA-virus proteases counteracting host innate immunity.Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus nsp3-4 Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication.The RNA-Binding Site of Poliovirus 3C Protein Doubles as a Phosphoinositide-Binding Domain.MERS-CoV papain-like protease (PLpro): expression, purification, and spectroscopic/thermodynamic characterization.Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.Introduction: celebrating the international year of crystallography: introduction.
P2860
Q27707324-5819935B-B9C6-4ACF-A217-B6F03A8D26C6Q30145557-36E61653-68DC-4744-894B-FB2AC1F18BB0Q34652842-7B115180-71A0-4CCB-8323-DE9AF0C9BE36Q35592656-DD035AE8-7058-4B0D-BE52-72D3E6EACFFCQ35973652-C088232F-8792-4B36-A3D0-7DD66DD90D92Q36053088-75DD996A-A4CB-4BA3-9CE8-07D639CF9645Q36657519-FD15B907-64CA-4B54-9AC4-6B66E4285647Q40066626-FDBDBC00-10BC-4167-A7F4-6754BEBFE2CCQ43280688-68CAAFAC-2DE5-4434-9EA8-2FD090535C20Q46033198-1ED56687-400E-4F1D-A9D1-755EF99252F3Q47323612-BBEF87D5-348B-4830-A6B4-4F2DE6F73474Q51795571-F5E7CD27-E1AD-483E-809D-2012D48AB589Q52653879-F736F271-CB04-4BBF-A27D-13006959D2F4Q53085611-A655A27C-4423-41AF-AE2E-C467EAD20C65
P2860
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@ast
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@en
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@nl
type
label
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@ast
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@en
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@nl
prefLabel
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@ast
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@en
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@nl
P2860
P921
P3181
P356
P1433
P1476
From SARS to MERS: crystallogr ...... s enable antiviral drug design
@en
P2860
P304
P3181
P356
10.1111/FEBS.12936
P407
P577
2014-09-01T00:00:00Z